Impact BioMedical, INC. Operating Income
Impact BioMedical, INC. (IBO) reported Operating Income of -$702.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-07
- Impact BioMedical, INC. operating income (loss) for the quarter ending 2026-06-30 was -$702.00K.
- Impact BioMedical, INC. operating income (loss) for the quarter ending 2026-03-31 was -$2.29M.
- Impact BioMedical, INC. operating income (loss) for the quarter ending 2025-12-31 was -$1.17M.
- Impact BioMedical, INC. operating income (loss) for the quarter ending 2025-09-30 was -$948.00K.
- Impact BioMedical, INC. operating income (loss) for fiscal 2025 was -$4.28M.
- Impact BioMedical, INC. operating income (loss) for fiscal 2024 was -$28.75M.
- Impact BioMedical, INC. operating income (loss) for fiscal 2023 was -$4.03M.
- Impact BioMedical, INC. operating income (loss) for fiscal 2022 was -$3.40M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$702.00K 10-Q · filed 2026-08-07 | -$2.99M 10-Q · filed 2026-08-07 | -$4.16M derived: sum of 3 quarters · filed 2026-08-07 | -$5.11M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-12 | -$3.46M derived: sum of 2 quarters · filed 2026-05-12 | -$4.41M derived: sum of 3 quarters · filed 2026-05-12 | -$5.56M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$2.12M derived: sum of 2 quarters · filed 2026-03-11 | -$3.27M derived: sum of 3 quarters · filed 2026-08-07 | -$4.28M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$948.00K 10-Q · filed 2025-11-07 | -$2.10M derived: sum of 2 quarters · filed 2026-08-07 | -$3.11M 10-Q · filed 2025-11-07 | -$29.34M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$1.15M 10-Q · filed 2026-08-07 | -$2.17M 10-Q · filed 2026-08-07 | -$28.39M derived: sum of 3 quarters · filed 2026-08-07 | -$29.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$1.01M 10-Q · filed 2026-05-12 | -$27.24M derived: sum of 2 quarters · filed 2026-05-12 | -$28.37M derived: sum of 3 quarters · filed 2026-05-12 | -$28.99M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$27.36M derived: sum of 2 quarters · filed 2026-03-11 | -$27.98M derived: sum of 3 quarters · filed 2026-03-11 | -$28.75M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$1.13M 10-Q · filed 2025-11-07 | -$1.75M derived: sum of 2 quarters · filed 2025-11-07 | -$2.52M 10-Q · filed 2025-11-07 | -$3.66M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$626.00K 10-Q · filed 2025-08-14 | -$1.40M 10-Q · filed 2025-08-14 | -$2.54M derived: sum of 3 quarters · filed 2025-08-14 | -$3.61M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$771.00K 10-Q · filed 2025-05-14 | -$1.91M derived: sum of 2 quarters · filed 2025-05-14 | -$2.99M derived: sum of 3 quarters · filed 2025-05-14 | -$4.00M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$2.22M derived: sum of 2 quarters · filed 2025-03-28 | -$3.23M derived: sum of 3 quarters · filed 2025-03-28 | -$4.03M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.08M 10-Q · filed 2024-11-12 | -$2.09M derived: sum of 2 quarters · filed 2024-11-12 | -$2.89M 10-Q · filed 2024-11-12 | -$3.92M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.01M 10-Q · filed 2024-08-13 | -$1.81M 10-Q · filed 2024-08-13 | -$2.84M derived: sum of 3 quarters · filed 2024-08-13 | -$3.73M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$803.00K 10-Q · filed 2024-05-10 | -$1.83M derived: sum of 2 quarters · filed 2024-05-10 | -$2.72M derived: sum of 3 quarters · filed 2024-05-10 | -$3.47M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$1.92M derived: sum of 2 quarters · filed 2024-02-20 | -$2.67M derived: sum of 3 quarters · filed 2024-02-20 | -$3.40M 10-K · filed 2024-02-20 |
| 2022-09-30 | -$889.00K 10-Q · filed 2023-11-13 | -$1.64M derived: sum of 2 quarters · filed 2023-11-13 | -$2.37M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$750.00K 10-Q · filed 2023-10-05 | -$1.46M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |